Archimed was a spin-out from Insense (qv) to commercialise wound dressing technology developed by Insense for the chronic wound care market – this is a growing market due to, inter alia, the increasing average age of populations and the growing incidence of diabetes.
In 2014, a restructuring resulted in the investment in Archimed LLP becoming a shareholding in Microarray Ltd, following the sale of Archimed LLP with its developed products – the rights to the principal product under development was excluded from the sale and transferred to Microarray.